Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes

Joan Prades a,⁎, Eline Remue b, Elke van Hoof c, Josep M. Borras a,d

a Catalan Cancer Plan, Duran i Reynals Hospital, 199–203 Gran Via de l’Hospitalet Av., Hospital de Llobregat, 08908 Barcelona, Spain
b Belgian Cancer Centre, Scientific Institute of Public Health, Rue Juliette Wysman 14, 1050 Brussels, Belgium
⁎ Experimental and applied psychology, Faculty of educational an psychology sciences, Vrije Universiteit Brussel, Brussels, Belgium
c Department of Clinical Sciences, Bellvitge Biomedical Research Institute (IDIBELL), University of Barcelona (UB), Spain

d Multidisciplinary teams (MDTs) are considered the gold standard of cancer care in many healthcare systems, but a clear definition of their format, scope of practice and operational criteria is still lacking. The aims of this review were to assess the impact of MDTs on patient outcomes in cancer care and identify their objectives, organisation and ability to engage patients in their care. We conducted a systematic review of the literature in the Medline database. Fifty-one peer-reviewed papers were selected from November 2005 to June 2012. MDTs resulted in better clinical and process outcomes for cancer patients, with evidence of improved survival among colorectal, head and neck, breast, oesophageal and lung cancer patients in the study period. Also, it was observed that MDTs have been associated with changes in clinical diagnostic and treatment decision-making with respect to urological, pancreatic, gastro-oesophageal, breast, melanoma, bladder, colorectal, prostate, head and neck and gynaecological cancer. Evidence is consistent in showing positive consequences for patients’ management in multiple dimensions, which should encourage the development of structured multidisciplinary care, minimum standards and exchange of best practices.

© 2014 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Optimal decision-making in the diagnosis, treatment and support of cancer patients is increasingly associated with multidisciplinary teams (MDTs) [1], an approach validated by experts at the EU level [2], pursued as a key objective in many cancer plans [3], and addressed by the European Commission through the European Partnership for Action Against Cancer (EPAAC) [4,5]. EPAAC addressed multidisciplinary care from a policy perspective in order to define the core elements that all tumour-based MDTs should include [4,5], in part in response to the significant variability observed in the aims, roles and organisational implications of MDTs, as well as differences in performance and access [6,7]. Indeed, the growing number of
multidisciplinary care studies overlap with evidence on the importance of caseload concentration [8–11], raising questions regarding the best approach to cancer care.

In this context, a review of the published studies on MDT clinical practice and organisation was undertaken for the purpose of assessing the evidence supporting this approach. An initial, comprehensive review of all papers published until 2005 had already been undertaken by Cancer Care Ontario (CCO) [12], a study which gave rise to the creation of a standards document on multidisciplinary cancer conferences. However, while the multidisciplinary approach was documented as influential in changing patient management plans, only limited evidence for the efficacy of multidisciplinary care demonstrated improved clinical outcomes [12]. The aims of this study were to assess the impact of MDTs on patient outcomes in cancer care and identify their objectives, organisation and ability to engage patients in the care process. The present paper sought to update this first review, including all the literature published subsequently up to June 2012.

2. Materials and methods

We undertook a literature search in the Medline database for peer-reviewed articles published between the third week of November 2005 and the end of June 2012 that examined multidisciplinary clinical practice and organisation in cancer care. We used the same search terms than Wright et al. did in case of the CCO review: 'tumo$r board$'; 'multidisciplinary conference$'; 'multi-disciplinary clinic$'; 'multidisciplinary team$'; and 'morbidity and mortality conference$'. The search was limited to papers’ titles and abstracts. We adopted a wide conceptual framework of multidisciplinary care by following the consensus definition reached by the healthcare working group of EPAAC: "Multidisciplinary teams (MDTs) are an alliance of all medical and health care professional- als related to a specific tumour disease whose approach to cancer care is guided by their willingness to agree on evidence-based clinical decisions and to coordinate the delivery of care at all stages of the process, encouraging patients in turn to take an active role in their care" [13]. Exclusion criteria were as follows: any paper whose main focus was not the MDT decision-making process; any paper in which the MDT, at least, did not include the medical specialties necessary for planning treatment; any paper focusing on paediatric patients; any review, editorial, comment, etc.; and any paper written in a language other than English. A flow chart listing all the papers retrieved and selected is shown in Fig. 1.

The selection of papers was conducted in four steps by two reviewers working independently (JP, ER). In the event of disagreement, a third reviewer reviewed the paper and made a final decision after careful discussion with the team, with the aim of reaching a consensus. Two types of original papers were included: the first comprised publications relating to the impact of MDT patient management on clinical and process outcomes (these typically compared multidisciplinary interventions to one-on-one settings, or before-and-after MDT performance); the second type included papers which contributed to improving cancer care. The latter was divided in three subsections: (1) MDTs’ mandate, (2) organisation and (3) patient engagement. With regard to the organisation, the following issues were included: format, team members, roles and responsibilities, data-management and support. Unlike the CCO review, and in recognition of its importance in the reviewed papers, “patient engagement” was also included as a theme. We opted for a narrative review because of the extreme difficulty entailed in conducting a quantitative assessment of the papers included, owing to the different end-points, populations and definitions of the variables used.

3. Results

Fifty-one papers were selected for inclusion in this review (see Fig. 1). The main characteristics of the papers included in the review are also presented (see Tables 1 and 2).

3.1. Impact on patient outcomes

Twenty-nine studies assessed the impact of MDT patient management on outcomes by linking outcome data to the introduction or presence of MDTs in different settings [14–42]. All studies concluded that a multidisciplinary setting resulted in improved patient outcomes in terms of diagnosis and/or treatment planning [14–16.18–22,25–29,31–33,35–37,40,42], improvements in survival [15,17,21,23,28–30,36,39,41], patient satisfaction [24,31,38] and clinician satisfaction as a consequence of teamwork communication and cooperation [15,34]. Evidence of improved survival was found for colorectal [15,17,28,36], head and neck [29,41], breast [39], oesophageal [21] and lung [30] cancer. MDTs contributed to changing clinical diagnostic and treatment decision-making with respect to urological [14], pancreatic [16], gastro-oesophageal [19,39], breast [20], melanoma [25], bladder [27], colorectal [22], prostate [42], head and neck [33] and gynaecological [35] cancer patients. The other 22 studies focused on the structure and functions related to MDT organisation by identifying how the format, data management and professional roles of MDTs impacted positively on care coordination for professionals and patients (Table 2).

3.2. MDT goals and scope of practice

MDTs mandate. The studies documented two motivating principles: firstly, MDTs ensure more appropriate treatment through a preoperative review of imaging and pathology results [19,20,22,25,26,40,42]; and secondly, a multidisciplinary approach guarantees the most up-to-date treatment for all cancer patients seen at the facility or discussed online [16,18,21,23,32,33,35,38–41,53]. Other clinical-based goals included improving patients’ quality of life [24,32,42,53–55] and setting up a structured follow-up care plan [53,59–61]. Concerning team performance, the main goals cited were improving coordination and continuity of care by reducing time from diagnosis to treatment (or access to MDTs) [30,35,38,58]; achieving early and appropriate referral patterns [17,26,32,45,49,51]; and
Table 1
Studies which demonstrated improved outcomes with multidisciplinary patient management.

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Endpoints assessed</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kurpad et al. [14]</td>
<td>Prospective cohort study of patients with urological malignancies (2007–2008)</td>
<td>Effect of MTM on diagnosis and treatment decisions</td>
<td>38% of patients had a change in diagnosis or treatment decisions</td>
</tr>
<tr>
<td>Segelman et al. [15]</td>
<td>Retrospective cohort study of county cancer registry data (1995–2004)</td>
<td>MDT assessment and treatment in patients with stage IV CRC</td>
<td>Metastasis surgery was more common among patients who were assessed than those who were not assessed by an MDT (6.9% vs. 1.2%, p &lt; 0.001)</td>
</tr>
<tr>
<td>Pawlik et al. [16]</td>
<td>Prospective cohort study of pancreatic cancer patients (2006–2007)</td>
<td>Clinical recommendations made with or without a ‘single-day’ MDC assessment for pancreatic cancer patients</td>
<td>23.6% of patients experienced a change with respect to their previous recommended therapeutic plan Increase patient access to clinical trials Increased tumour-registry enrolment (from 49.2% to 77.8%)</td>
</tr>
<tr>
<td>Lordan et al. [17]</td>
<td>Prospective study (1996–2006) comparing CRC patients referred to an MD specialist hepatobiliary unit (with liver surgeon) vs. local CRC MDTs</td>
<td>1-, 3-, and 5-year survival for patients who develop colorectal liver metastases</td>
<td>Patients referred to the MD unit had 1-, 3-, and 5-year survival rates of 89.6%, 67.5%, and 49.9% vs. 90.3%, 54.1%, and 43.3% respectively among those referred to local MDTs</td>
</tr>
<tr>
<td>Chekerov et al. [18]</td>
<td>Questionnaire to participants of an online tumour conference for complex gynaecological cases</td>
<td>Physicians acceptance and satisfaction with online national TB</td>
<td>78% of recommendations were accepted and implemented 88% of participants considered there was benefit for their clinical practice</td>
</tr>
<tr>
<td>Davies et al. [19]</td>
<td>Prospective cohort study (1997–2002)</td>
<td>Staging accuracy and treatment selection of gastro-oesophageal patients</td>
<td>MDT staging and assessment of nodal disease were more accurate than each individual staging modality for T and N staging</td>
</tr>
<tr>
<td>Newman et al. [20]</td>
<td>Retrospective review of medical records (2000–2001)</td>
<td>Effect of breast TB recommendations on patients looking for a second opinion</td>
<td>52% of patients had changes in recommendations for surgical management</td>
</tr>
<tr>
<td>Stephens et al. [21]</td>
<td>Retrospective case-control study of patients managed by an MDT (1998–2003) or by surgeons working independently (1991–1997)</td>
<td>Outcomes after surgery for oesophageal cancer</td>
<td>Lower operative mortality (5.7% vs. 26%, p = 0.0004) and higher survival (52% vs. 10%, p = 0.0001) among MDT patients than those managed by general surgeons</td>
</tr>
<tr>
<td>Burton et al. [22]</td>
<td>Retrospective cohort study of rectal cancer patients (1999–2002), comparing CRM+ ve rates of patients discussed vs. those not discussed at MTM</td>
<td>Impact of preoperative MRI-based MDT discussion on treatment strategy</td>
<td>MDT discussion of MRI resulted in CRM+ in 1% of patients (1 out of 116) vs. 26% of those (16 out of 62) without MDT discussion</td>
</tr>
<tr>
<td>Nguyen et al. [23]</td>
<td>Retrospective cohort study (1997–2006) of locally advanced head and neck cancer patients</td>
<td>Survival of postoperative radiation and chemoradiation groups of patients, based on TB recommendations</td>
<td>TB patient survival rate was comparable to those reported by RCT</td>
</tr>
<tr>
<td>Ibrahim et al. [24]</td>
<td>Observational retrospective study (2005–2008) of an osteo-oncology centre and use of questionnaires</td>
<td>Patient satisfaction</td>
<td>75% of patients were very satisfied with the service provided 74% of patients were not disturbed by MD visits</td>
</tr>
</tbody>
</table>
| Santillan et al. [25]             | Retrospective cohort study of melanoma cancer patients (2006–2009)            | Diagnosis and staging review of patients referred from an outside facility and impact on surgical recommendations | 3% of invasive thin melanoma patients and 6% of in situ melanoma patients had changes in interpretation 28% of ITM patients were restaged (13% upstaged, and 13% downstaged) 12% of patients (7%, smaller excision margin; 5%, wider margin) had changes with respect to primary lesion in recommended surgical excision margins
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Endpoints assessed</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sooriakumaran et al. [26]</td>
<td>Retrospective review of urological patients (2007)</td>
<td>Impact on management decisions by a central MDT with respect to referred cases from a local MDT</td>
<td>21% of bladder cancer patients had their treatment plan changed. 9% of prostate cancer patients were excluded from/recommended for clinical trials. One kidney cancer patient had his treatment-plan decision changed.</td>
</tr>
<tr>
<td>Pituskin et al. [27]</td>
<td>Prospective study of bone metastases patients referred to an outpatient palliative RT clinic (2007)</td>
<td>Impact of a systematic multidisciplinary screening and non-physician assessment on recommendations for patient management</td>
<td>Symptom improvement in pain, tiredness, depression, anxiety, drowsiness and overall wellbeing (reported at 4 weeks)</td>
</tr>
<tr>
<td>Du et al. [28]</td>
<td>Retrospective review of rectal cancer patients (2001–2005), comparing patients receiving MDT treatment vs. those receiving direct surgery</td>
<td>Effect of MDT discussion on treatment selection and outcomes</td>
<td>37.1% sphincter preservation in the MDT vs. 13.5% in the non-MD subgroup (p &lt; 0.005) 77.2% 5-year survival rate in the MDT group vs. 69.7% in the non-MDT group (p = 0.049)</td>
</tr>
<tr>
<td>Friedland et al. [29]</td>
<td>Retrospective review of hospital registry database and head and neck cancer clinic (1996–2008), comparing outcomes of patients managed by an MDT and individual disciplines</td>
<td>Survival of head and neck cancer patients and clinical management factors</td>
<td>Higher survival for MDT patients compared to individually managed patients (HR = 0.69; 95% CI = 0.51–0.88 at 5-year survival for stage IV patients). More synchronous chemotherapy and radiotherapy in MDT patients (p = 0.004)</td>
</tr>
<tr>
<td>Bydder et al. [30]</td>
<td>Prospective study of hospital cancer registry database (2006), comparing lung cancer patients discussed vs. those not discussed at MTMs</td>
<td>Impact on treatment and survival of patients with inoperable NSCLC</td>
<td>33% 1-year survival among NSCLC patients discussed vs. 18% among those not discussed (p = 0.0478)</td>
</tr>
<tr>
<td>Caudron et al. [31]</td>
<td>Retrospective study of skin cancer patients (2006–2007)</td>
<td>Evaluation of MTM functioning and decision-making process</td>
<td>88% of MTM recommendations were implemented. 49.4% of patients attended their MTM. MTMs (some sub-groups) received better treatment (access to radiotherapy, chemotherapy and palliative care)</td>
</tr>
<tr>
<td>Boxer et al. [32]</td>
<td>Retrospective review of regional cancer registry and MDT database (2005–2008), comparing lung cancer patients presented vs. those not presented at MTM</td>
<td>Impact of MDT discussion on patterns of care, survival and quality of life</td>
<td>80% of patients had their treatment plan changed (p = 0.0212)</td>
</tr>
<tr>
<td>Wheless et al. [33]</td>
<td>Prospective study of head and neck cancer patients (2009–2010), comparing benign and malignant cohorts</td>
<td>Effect of TB discussion on diagnosis, stage and treatment plan decisions</td>
<td>27% of all patients had some change in diagnosis and treatment. 65% of the malignant cohort patients experienced the addition of a treatment modality (p = 0.0212)</td>
</tr>
<tr>
<td>Field et al. [34]</td>
<td>Survey of neuro-oncology MTM attendees (2009)</td>
<td>Clinician satisfaction with MTMs and documentation procedures</td>
<td>100% felt that the MTM and its documentation procedures were very or extremely important. 94% felt that the MTM was effective in the documentation and communication of plans</td>
</tr>
<tr>
<td>Freeman et al. [35]</td>
<td>Retrospective cohort study of oesophageal cancer patients, comparing patients treated before and after the initiation of the MD conference (2001–2007)</td>
<td>Impact of the MD thoracic malignancy conference in patient care and adherence to NCCN guidelines</td>
<td>97% of MD vs. 67% of non-MD patients received complete staging evaluation (p &lt; 0.0001) 98% of MD vs. 72% of non-MD patients had multidisciplinary evaluation before treatment (p &lt; 0.0001). Adherence to NCCN guidelines was 98% in MD and 83% in non-MD patients (p &lt; 0.0001)</td>
</tr>
</tbody>
</table>

ARTICLE IN PRESS
Table 1 (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Type of study</th>
<th>Endpoints assessed</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Palmer et al. [36]</td>
<td>Retrospective cohort study of population-based registry (1995–2005), comparing tumour staging and outcomes of locally advanced rectal cancer patients with or without MDT assessment</td>
<td>Effect of MDT assessment in preoperative local and distant staging on management and outcome</td>
<td>Incidence of R0 resection was 52% in MDT vs. 43% in non-MDT patients (p &lt; 0.001). Local tumour control was 57% in MDT vs. 36% in non-MDT patients (p &lt; 0.001). Five-year survival was 30% among MDT vs. 28% among non-MDT patients (p = 0.002). 74% of patients had changes in diagnosis, a discrepancy that altered their treatment plan by 27% of patients.</td>
</tr>
<tr>
<td>Greer et al. [37]</td>
<td>Retrospective study of gynaecological cancer patients (2004–2006)</td>
<td>Impact of TB on patient management</td>
<td>Time from diagnosis (biopsy) to treatment was reduced to a mean of 18 vs. 24 days before MDC implementation.</td>
</tr>
<tr>
<td>Bjegovich-Weidman et al. [38]</td>
<td>Retrospective and descriptive study of a lung cancer MDC</td>
<td>Time to treatment</td>
<td>At 5 years, breast cancer mortality was 18% lower and all-cause mortality was 11% lower in the intervention area than in the non-intervention area.</td>
</tr>
<tr>
<td>Kesson et al. [39]</td>
<td>Retrospective, comparative, non-randomised, interventional cohort study of breast cancer patients (1990–2000)</td>
<td>Cancer-specific mortality and all-cause mortality between two neighbouring areas before and after the introduction of MDTs</td>
<td>Complete pre-operative evaluation in MDC patients was 85% vs. 23% in the control group (p = 0.0001). 22.5% of MDC patients vs. 41.5% of control group patients had peri-operative treatment (p = 0.02). 76% of MDC rectal cancer patients vs. 20% of control group patients underwent neoadjuvant therapy (p &lt; 0.0001).</td>
</tr>
<tr>
<td>Levine et al. [40]</td>
<td>Prospective study of CRC patients (2008–2009), comparing patients referred to the MDC vs. patients managed outside</td>
<td>Comprehensiveness of the preoperative evaluation, and access to multimodal care</td>
<td>Higher survival among MDT-participant vs. non-participant patients (HR = 0.84; 95% CI = 0.78–0.90 at 5-year survival for MDT patients).</td>
</tr>
<tr>
<td>Wang et al. [41]</td>
<td>Retrospective, longitudinal cohort study of national health database (2004–2008), comparing participation/non-participation of patients in MDT care</td>
<td>Survival and effects of MDT care on oral cavity cancer patients</td>
<td>Higher survival among MDT-participant vs. non-participant patients (HR = 0.84; 95% CI = 0.78–0.90 at 5-year survival for MDT patients).</td>
</tr>
<tr>
<td>Korman et al. [42]</td>
<td>Retrospective cohort study of MDC database and hospital registry (2006–2011), comparing patients treated before and after the initiation of an MDC</td>
<td>Impact on prostate and genitourinary patient treatment decisions and adherence to NCCN guidelines</td>
<td>41% of low-risk MDC vs. 27% of non-MDC patients chose external beam radiation therapy (p = 0.02). 30% of MDC vs. 44% of non-MDC patients chose prostatectomy (p = 0.03). 14% of MDC vs. 61% of non-MDC patients chose active surveillance (p = 0.02). Adherence to NCCN guidelines was 90% among intermediate-risk MDC patients vs. 76% among non-MDC patients (p = 0.01).</td>
</tr>
</tbody>
</table>

**Abbreviations**: circumferential resection margin (CRM); colorectal cancer (CRC); magnetic resonance imaging (MRI); multidisciplinary (MD); multidisciplinary clinics (MDC); multidisciplinary team meeting (MTM); multidisciplinary team (MDT); National Comprehensive Cancer Network (NCCN); non-small cell lung cancer (NSCLC); radiotherapy (RT); randomised controlled trial (RCT); tumour board (TB); tumour node metastasis (TNM).
maintaining a commitment to research and clinical trials [15,16,18,26,38,43,44,56,57]. Secondary objectives also included providing a teaching environment for healthcare professionals and junior doctors [18,20,24,30,32,34,54]; acting as a quality improvement group [22,34,50,54]; and increasing enrolment in the tumour registry [16].

3.3 MDT organisation

Format. Even though MDT meetings were usually held once a week, different organisational practices were used depending on the format of the MDT (see Table 2). Essentially, there were three types of formats in clinical practice. Firstly, there were meetings, which lasted anywhere from 30 min to 2 h and included either all or a selection of diagnosed and/or referred patients; patients were selected by the specialist in charge based on the case’s level of complexity or the wide range of therapeutic possibilities, prearranged team criteria, or triage by the clinical coordinator [27,30,32–34,46,48,50]. A second MDT format was the multidisciplinary clinic, where patients were not only seen but also simultaneously examined [16,38,40,53,54] or remotely coordinated by all board members [42]. Finally, online conferences made use of specific web-based software to organise and conduct online tumour board meetings among clinicians within a given hospital [16] or nationwide [18].

Meeting presentations involved prospective reviews of new and recurrent cases, previously reviewed cases requiring additional follow-up [29,33], and second opinions, which were seen as useful for patients and physicians when faced with difficult treatment decisions [18,20,38].

Attendance at meetings, whatever their format, varied significantly.

Team members. MDT membership and attendance at meetings varied according to hospital size and medical specialty. Other important predictors were cancer type, format of the delivery setting, and perceived efficiency of the meeting performance [45,50–52,62]. Several papers differentiated team composition by identifying three levels of involvement, i.e., “core”, “allied” (or “extended”) and “expert support” membership. Core and allied members included radiologists, pathologists, surgeons, radiation and medical oncologists, oncology nurses, palliative care physicians, head and neck specialists, nuclear medicine specialists, respiratory disease physicians, gastrointestinal disease physicians and anaesthesiologists, some of whom were frequently sub-specialised by tumour site [20,29,30,32–34,42,43,45,52,53]. The support members included psychologists, nutritionists, dieticians, plastic surgeons, speech therapists, patients’ GPs, physiotherapists, practitioners of complementary medicine, orthopaedic specialists, medical physicists, odontologists, faith counsellors, biologists, data managers, genetic counsellors, hospital pharmacists, social workers and occupational therapists [24,27,40,45,49,54,55].

Roles and responsibilities. A number of studies examined the role of a designated coordinator or chairperson in ensuring the smooth functioning of the MDT setting. The different scopes of coordination and the need to adapt to particular practice contexts implied the problem of finding ‘equivalents’ of the role and defining consistent profiles. Nonetheless, an analysis of the studies allowed the differentiation between ‘inward’ responsibilities (MDT organisation and efficient direction) and
'outward' responsibilities (clinical management of the care plan). Whereas inward responsibilities consisted of scheduling agendas for meetings, drawing up the list of patients to be discussed, ensuring that all necessary tests were obtained and available in advance of the discussion, and recording the MDT decisions and rationales agreed [34,38,42,45,46], outward tasks entailed communicating decisions to patients/families, GPs, providers and referring physicians, as well as coordinating outpatient visits and referrals from satellite centres, and facilitating the link to research either directly or by improving liaison with the clinical trial coordinator [24,32,34,38,42,43,53,54]. Other studies documented the role of clinical nurses in guiding the patient through the care pathway or assuming the task of coordinating the follow-up [29,40,42,43,45,47,53–55,58–61,63]. The main responsibilities fulfilled by nurses were: providing psychosocial support and education to the patient; managing treatment-related toxicities and side-effects; coordinating services (diagnostic and treatment agenda); facilitating liaison with external support services; managing patient transition across the cancer network; and acting as a focus of communication between team and patient.

Data management and support. The use of information technology (IT) was commonly described as a useful way of sharing patient details and providing documentation, such as the minutes of an MDT meeting aimed at setting up a prospective clinical database. Several studies showed how hospital intranets allowed for a password-protected view of virtual MDT meeting minutes, which were embedded or developed within the same system. Repeated reference was made to the need to clarify how and why final decisions were reached. Some papers mentioned the importance of available facilities, such as a meeting room with good acoustics, computer access at all sites within a cancer network, and a telephone number to provide centralised access to patients managed by the case nurse manager. The decision to overcome logistics-related barriers through the medium of online video-conferences and the use of IT to share radiology and histopathology images, were also described and examined. Finally, the need to support MDTs’ clerical and general administrative activity was highlighted [18,30,32,34,42,45,50,52].

3.4. MDT patient engagement

Communication with and delivery of information to patients. A number of studies reflected a desire to involve patients actively in their care and promote greater understanding of the specific collaborative MDT intervention. Indeed, some expressly mentioned that the MDT rationale had been explained to the patient [23,24]. Treatment, toxicities, side effects, complications and information on second- and third-line treatments after recurrent disease were variously reported as having been discussed with patients before making decisions, sometimes by using written materials or by providing access to psychologists or social workers [18,20,23,38,42,52,53,56,58,59,61,64]. A number of papers identified the need to take into account patients’ physical and psychological comorbidities when making clinical decisions; furthermore, they noted that

Please cite this article in press as: Prades J, et al. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy (2014), http://dx.doi.org/10.1016/j.healthpol.2014.09.006
special attention should be paid to the same clinical message and bridging gaps between teams and patients, as well as clearly setting out how to deal with the complexities of the health care system [43,44,53,54,56,60,63]. Other studies addressed issues such as the patient-doctor relationship within a multidisciplinary setting, the impact of pre-existing knowledge of the patient in MDT discussions, patient attendance at and involvement in MDT meetings, and the way in which the patients are approached to participate in clinical trials [46,48,56,64]. The need to facilitate access to community resources, namely, patient support groups, libraries and volunteers, was also described [54,55,58].

4. Discussion

This review showed that MDTs resulted in better clinical and process outcomes for cancer patients, with evidence of improved survival among colorectal [15,17,28,36], head and neck [29,41], breast [39], oesophageal [21] and lung [30] cancer patients across the study period (2005–2012). Mention should likewise be made of the contribution made by MDTs in changing clinical diagnostic and treatment decision-making with respect to urological [14], pancreatic [16], gastro-oesophageal [19,35], breast [20], melanoma [25], bladder [27], colorectal [22], prostate [42], head and neck [33] and gynaecological [35] cancer patients. The paper from Kesson et al. merits a specific mention since it used an interrupted time series analysis in order to assess the impact of MDTs in one intervention area, demonstrating a significant improvement in survival [39].

A number of studies also showed the growing importance of organisation in ensuring smooth teamwork. These papers showed that collaboration transcends the setting of individual meetings held to make key clinical decisions. Instead, such an organisational mechanism—tumour board, cancer conference or other—evolves into the epicentre of a streamlined, comprehensive management approach made up of different components and interfaces, from diagnosis to treatment and follow-up. For example, MDT members undertook the role of ‘agent’ in explaining to patients the possibility of entering clinical trials in order to improve recruitment [43,44,56,57]; participated in tumour-based collaboration with psycho-oncologists and palliative care teams to improve care processes for advanced cancer patients [49]; and empowered nurse case managers to ensure continuity of care for patients within a network [58], coordinating follow-up programmes [59], or managing follow-up with other healthcare providers [55,60,61]. These examples involved an extension of specialised access and team control that goes beyond the treatment stage. It is worth highlighting the amount of attention paid to maintaining consistent communication and delivery of information between the team and the patient. Explanations for this included the need to improve management of therapy-induced adverse effects and, in a broad sense, quality-of-life aspects, both of which call for patients and families to play an active role [16,22,33,48,53,54].

Two prominent MDT organisational approaches emerged in our analysis: on the one hand, meetings or conferences in Europe, Australia and Canada, and on the other, clinics in the USA. The former entails some degree of clinical service cooperation or unit integration in a new scenario, in contrast to the traditionally fragmented one that prevailed before the introduction of the MDT. The latter, often called ‘one-stop care’, generally seeks to concentrate team efforts at a specific moment in time, usually through patient examinations by all board members, subsequent group discussion and then proposal of a treatment plan. One leading argument put forward to support this approach in the USA is that it prevents outward migration to competing providers [38]. Nonetheless, organisational variables, such as team composition, have been shown to be associated with the quality of clinical care [65]. Although several papers reflected that MDTs worked in accordance with a regional or national policy strategy [20–22,26,29,31,34,41,44–52] (with some exceptions [16,69,70]), teamwork was rarely framed by specific policy guidance. Its absence led to some problems, for instance, emotional exhaustion among team leaders and clinical nurses owing to the lack of defined professional roles and team training [43,63]. As Ruhstaller et al. proposed, efforts should be made to develop the ‘theoretical MDT model’ in order to avoid situations such as the involvement of professionals who are unfamiliar with patients in decision-making that affects them [7].

Several questions have also been raised regarding the quality of the evidence. Some authors discussed the lack of rigorous methodology, design and clear definitions of multidisciplinary cancer care models in studies aimed at ascertaining the effectiveness or overall impact of teamwork on outcomes or process measures [66,67]. It has to be said that, when it comes to inferring a direct causal relationship between interventions that depend on an MDT context and clinical outcomes, the evidence is limited. Indeed, most of the initial papers were based on observational retrospective data and thus afford only weak support for the hypothesis from a methodological point of view. Yet, this review found a significant number of prospective studies which report clinical benefits based on changes in diagnostic and treatment decisions, and so provide better evidence of the effectiveness of MDTs [14,16,17,19,27,30,33,40].

There were a number of differences with respect to the systematic review conducted by Wright et al. for the period 1960–2005. Firstly, there was a wide variation in the types of tumours studied (e.g., bone metastasis, skin or brain cancer) and a marked increase in papers discussing colorectal, head and neck, and prostate and genitourinary neoplasms. This can be explained by the increasing number of different therapeutic options at several tumour sites, some of which rely to a major degree on the involvement of different medical specialties, such as preoperative radiochemotherapy for rectal cancer [68]. Also, whereas the papers’ main clinical focus was the therapeutic decision-making context, the role of MDTs tended to expand and embrace the whole process of care, from patient diagnosis to follow-up (see Table 3). This, together with the presence of studies showing enhanced access to palliative care teams and clinical trial coordinators, is an indicator of the wider perspective taken by research with respect to the impact of MDTs. In any case, findings yielded from this research strengthen...
the evidence base gathered from Wright et al.’s review and provide further support for the MDT approach to cancer care.

The delivery of cancer care is constantly challenged by changes in the supply side. Elements such as the increased complexity of multi-modal treatments and the emergence of new areas of cancer care intervention (e.g., genetic counselling, oncogeriatrics, survivorship, etc.) lead to a broader remit, bigger MDTs consisting of different levels of professional involvement, and an increased need for an active chair. Moreover, it is not rare for expert MDTs to work at different levels of clinical complexity, either embedded in cancer networks or fostering inter-hospital cooperation at a clinical level. Since professionals, rather than managers, are the operational nodes arranging the daily life of these connections, their ability to cooperate as a multidisciplinary team, in their own hospital, is critical.

Thus, it seems essential to formalise the necessary organisational adjustments, identifying the tumour-based MDTs as a specific area for clinical management. This approach implies shifting health services so that clinical departments’ interest and pathology programmes coalesce in a matrix pattern. An effective multidisciplinary model of cooperation is enabled when control over pathology-related decision-making processes is decentralised towards MDTs. Regardless of how they are integrated into cancer services (through the establishment of multidisciplinary clinics, meetings, etc.), a reorganisation following such a path requires a definition of MDT boundaries and scope of practice, promoting adherence to the coordination mechanisms put in place, providing administrative support, and promoting team roles and distributed leadership compatible with traditional hierarchies. Policymakers and hospital managers may greatly contribute to the effectiveness and stability of this system by articulating these operating conditions, stimulating clinical accountability for the decisions made and ensuring liability on patients’ clinical pathway, including in communication with them [71].

Cancer policy and health system funding are focused on structures, not on specific organisational approaches. However, the starting point should be recognising that hospital performance in cancer care is increasingly dependent on more complex and multidisciplinary decision-making processes and models of care, in which crosscutting roles, sub-specialised teams and clinical networks are of central importance [72].

As health systems increasingly pursue patient-centred approaches that treat people, rather than diseases, new dimensions of care have emerged as critical, including psychosocial aspects, quality of life, patients’ rights and empowerment, comorbidities and survivorship. These new complexities introduce challenges in communication, coordination and organisation, but they also promise a more holistic care model and ultimately, better patient outcomes [13]. MDTs are the cornerstone of such an approach and as such, they merit careful study in order to optimise their operation.

In order to better assess the results of our study, some limitations should be taken into account. First of all, the review of the literature was necessarily narrative, since a quantitative impact analysis was not considered feasible in view of the diversity of end points, definitions of variables and health care contexts. Grey literature was not included and thus no mention was made of the situation of multidisciplinary care reflected in reports and other sources. Lastly, the conceptual variability in the use of terms, such as multidisciplinary management, multidisciplinary protocols and clinical guidelines, negatively affected the literature search and increased the efforts required to include all the papers published under an umbrella of similar terminology. There is a clear need to reach some consensus about the terminology employed and what it is implied by each concept used to describe clinical practice.

5. Conclusions

Advantages in the adoption of a multidisciplinary approach do not result inevitably from the will to implement it on the basis of a policy decision [43]. Thus, specific guidance, team training and investment of resources—along with further research—are needed. In the case of resources, our research uncovered a growing gap among MDTs with respect to two functional dimensions. On the one hand, while some teams favour the celebration of physical meetings, others show a rapid adoption of IT for data-management and communication, a potential enabler to overcome logistical barriers in the context of a network of hospitals. On the other hand, teamwork seems to be especially reinforced when clinical data recording can be evaluated in-house or linked to cancer registries or administrative databases, which is usually not the case. Finally, although many papers set up clear roles for MDT membership by identifying “core” and “alliance” members, most papers were not clear about whether all patients should benefit from multidisciplinary management, or just some.

In brief, the rationale behind the more comprehensive structuring of teamwork in cancer care goes beyond eventual clinical outcomes and embraces the process of care as a whole. At the same time, however, analysing the outcomes demonstrates that the lack of clear, uniform operational criteria when it comes to MDTs is a drawback. Bearing in mind the growing trend in Europe towards tumour-based specialisation and concentration of services for complex cancer treatments, efforts should be made to define the critical elements of MDT models, elucidate their specific

Please cite this article in press as: Prades J, et al. Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy (2014), http://dx.doi.org/10.1016/j.healthpol.2014.09.006
advantages and outline what resources are needed for implementation.

Role of the funding source

This work was supported by EPAAC and Carlos III Institute of Health Research (Instituto de Salud Carlos III - ISCIII) in the form of research grants to the Cancer Research Network (RD 12/0036/0053), which provided financial support for the conduct of the research. The funders had no role in the study design, data collection and analysis.

Conflicts of interest

None to declare.

Acknowledgements

We should like to acknowledge the support received from the Carlos III Institute of Health Research. This project was undertaken within the framework of the European Partnership for Action Against Cancer (EPAAC). We are most grateful for the help received from Saskia Van den Bogaert (Federal public service health, food chain safety and environment, Belgium) in preparing the work.

References


[51] Prades J, Borrás JM. Multidisciplinary cancer care in Spain, or when the function creates the organ. BMC Public Health 2011;11:141.


[56] Maslin-Prothero S. The role of the multidisciplinary team in recruiting to cancer clinical trials. European Journal of Cancer Care (English) 2006;15:146–54.


